NO306850B1 - Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom - Google Patents

Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom

Info

Publication number
NO306850B1
NO306850B1 NO934059A NO934059A NO306850B1 NO 306850 B1 NO306850 B1 NO 306850B1 NO 934059 A NO934059 A NO 934059A NO 934059 A NO934059 A NO 934059A NO 306850 B1 NO306850 B1 NO 306850B1
Authority
NO
Norway
Prior art keywords
pyrimidinone
halo
deoxyribose
medicament
manufacture
Prior art date
Application number
NO934059A
Other languages
English (en)
Norwegian (no)
Other versions
NO934059D0 (no
NO934059L (no
Inventor
Yung-Chi Cheng
Chien-Neng Chang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of NO934059D0 publication Critical patent/NO934059D0/no
Publication of NO934059L publication Critical patent/NO934059L/no
Publication of NO306850B1 publication Critical patent/NO306850B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO934059A 1991-05-15 1993-11-09 Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom NO306850B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70146291A 1991-05-15 1991-05-15
US82947492A 1992-02-03 1992-02-03
PCT/US1992/004142 WO1992020816A1 (en) 1991-05-15 1992-05-15 Determination of prodrugs metabolizable by the liver and therapeutic use thereof

Publications (3)

Publication Number Publication Date
NO934059D0 NO934059D0 (no) 1993-11-09
NO934059L NO934059L (no) 1993-12-30
NO306850B1 true NO306850B1 (no) 2000-01-03

Family

ID=27106792

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934059A NO306850B1 (no) 1991-05-15 1993-11-09 Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
NO992273A NO308884B1 (no) 1991-05-15 1999-05-11 Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO992273A NO308884B1 (no) 1991-05-15 1999-05-11 Anvendelse av 5-halo-2-pyrimidin-deoksyribose eller 5-halo- pyrimidinon for fremstilling av et medikament for behandling av kreft

Country Status (13)

Country Link
US (1) US5728684A (ja)
EP (1) EP0586523A4 (ja)
JP (1) JPH06507902A (ja)
KR (1) KR100245252B1 (ja)
AU (1) AU673803B2 (ja)
BG (1) BG98217A (ja)
CA (1) CA2103050A1 (ja)
HU (1) HUT67392A (ja)
IE (1) IE921581A1 (ja)
IL (1) IL101879A (ja)
NO (2) NO306850B1 (ja)
RU (1) RU2126255C1 (ja)
WO (1) WO1992020816A1 (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9600847D0 (en) 1996-01-16 1996-03-20 Smithkline Beecham Plc Pharmaceuticals
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
WO2000013708A1 (en) * 1998-09-04 2000-03-16 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
EP1169322B8 (en) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal analogues for the treatment of disorders caused by a deficiency in vitamin b6
WO2001003745A2 (en) * 1999-07-09 2001-01-18 Board Of Regents Of University Of Nebraska Therapy and diagnosis of colorectal cancer with radiopharmaceuticals
WO2001003682A2 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
CA2383252A1 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
PT1268498E (pt) 2000-02-29 2005-07-29 Medicure Int Inc Fosfonatos cardioprotectores
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
WO2003012051A2 (en) * 2001-07-31 2003-02-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
US7015022B2 (en) * 2002-06-07 2006-03-21 University Of Medicine & Dentistry Of New Jersey Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
WO2006002549A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
JP2008517956A (ja) * 2004-10-28 2008-05-29 メディキュア・インターナショナル・インコーポレーテッド 二重の抗血小板性／抗凝固性ピリドキシン類似体
KR20080023680A (ko) 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체
WO2007059631A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
AP2011005929A0 (en) * 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
RU2522548C2 (ru) * 2012-09-26 2014-07-20 Федеральное государственное бюджетное учреждение науки Институт кристаллографии им. А.В. Шубникова Российской академии наук (ИК РАН) Ингибитор уридинфосфорилаз
RU2527457C2 (ru) * 2012-09-27 2014-08-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Ингибиторы поли(адф-рибозо)полимеразы-1 человека на основе производных урацила
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
EP3204043B1 (en) 2014-10-07 2023-06-07 Kinsella, Timothy J. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH 5-IODO-2-PYRIMIDINONE-2'-DEOXYRIBOSE (IPdR)
CA3049251A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Inc. Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation
WO2018148580A1 (en) * 2017-02-09 2018-08-16 Perfect Daylight Limited Methods for autism spectrum disorder pharmacotherapy
WO2021020979A1 (en) 2019-07-31 2021-02-04 Memorial Sloan Kettering Cancer Center Perfusion modulated tumor dose sculpting with single dose radiotherapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782142A (en) * 1982-01-05 1988-11-01 The Research Foundation Of State University Of New York Novel 5-substituted 2-pyrimidinone nucleosides and methods of use
US4895937A (en) * 1982-01-05 1990-01-23 The Research Foundation Of State University Of New York 5-ioso-2-pyrimidinone nucleoside
US4468384A (en) * 1982-01-05 1984-08-28 The Research Foundation Of State University Of New York Method for the inhibition of the replication of DNA viruses with 5-substituted 2-pyrimidinone nucleosides
ES2039615T3 (es) * 1987-03-16 1993-10-01 The Wellcome Foundation Limited Un procedimiento para la preparacion de nucleosidos.
US4942226A (en) * 1988-12-29 1990-07-17 Merck & Co., Inc. Halogenated pyrimidine nucleosides and their derivatives
DK0539442T3 (da) * 1990-07-19 1998-09-07 Wellcome Found Enzyminaktivatorer
GB9020930D0 (en) * 1990-09-26 1990-11-07 Wellcome Found Pharmaceutical combinations

Also Published As

Publication number Publication date
RU2126255C1 (ru) 1999-02-20
NO934059D0 (no) 1993-11-09
IL101879A (en) 1998-06-15
IE921581A1 (en) 1992-11-18
NO934059L (no) 1993-12-30
AU673803B2 (en) 1996-11-28
NO308884B1 (no) 2000-11-13
KR100245252B1 (ko) 2000-03-02
BG98217A (bg) 1995-02-28
EP0586523A4 (en) 1995-11-29
WO1992020816A1 (en) 1992-11-26
HU9303237D0 (en) 1994-03-28
NO992273D0 (no) 1999-05-11
HUT67392A (en) 1995-04-28
AU1998292A (en) 1992-12-30
IL101879A0 (en) 1992-12-30
CA2103050A1 (en) 1992-11-16
JPH06507902A (ja) 1994-09-08
EP0586523A1 (en) 1994-03-16
US5728684A (en) 1998-03-17
NO992273L (no) 1999-05-11

Similar Documents

Publication Publication Date Title
NO306850B1 (no) Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
DE69430693D1 (de) Medizinisches Beatmungsgerät
AU1197992A (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
DE69327153D1 (de) Anti-hiv-medikament
FI930674A (fi) Terapeutiska aemnen
DE69219279D1 (de) Hautreinigungsmittel
LV12067A (lv) 17B-N-vienaizvietota-karbamoil-4-aza-5alfa-androst-1-en-3-onu pielietojums medikamenta razosanai
FI931071A (fi) Terapeutiska aemnen
ITMI912224A1 (it) Impiego di composti adenosinici nel trattamento dell'ischemia
DE69122764D1 (de) Arznei gegen hornhautbeschädigungen
FI920701A (fi) Anordning foer terapeutisk tryckbehandling
FI924015A (fi) Anordning foer medicinsk behandling av kroppsdelar
KR930702972A (ko) 신질환치료제
DE69126217D1 (de) Respirationskatheter
SE9000231D0 (sv) Laekemedel med antidopamineffekt
SE9003275D0 (sv) Laekemedel med antidopamineffekt
UA15909A1 (uk) Засіб лікуваhhя хроhічhих паhкреатитів
KR910013986U (ko) 치료용 복대
KR930703003A (ko) 피부질환치료용 제약 조성물
DK681288D0 (da) Aenootropt terapeutisk laegemiddelae
SE9203298D0 (sv) Laekemedel med antidopamineffekt
ITMI910843A0 (it) Medicamento contenente "diidroergocriptina ad azione neuroprotettrice

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2001